Multidisciplinary outpatient congestive heart failure clinic: Impact on hospital admissions and emergency room visits

Canadian Journal of Cardiology

Volumn 20, Issue 12, 2004, Pages 1205-1211

  Martineau, Pierre ^a,b   Frenette, Marc ^b   Blais, Lucie ^b   Sauvé, Claude ^b  

^a PFIZER INC   (United States)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

ACE inhibitors; Beta blockers; Congestive heart failure; Diuretics; Multidisciplinary outpatient clinic

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; LISINOPRIL; METOPROLOL; QUINAPRIL; RAMIPRIL; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG DOSE REGIMEN; EMERGENCY WARD; FEMALE; HEART EJECTION FRACTION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; AMBULATORY CARE FACILITIES; CARDIOTONIC AGENTS; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEALTH SERVICES RESEARCH; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PATIENT READMISSION; PROBABILITY; PROGNOSIS; QUEBEC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME; UTILIZATION REVIEW;

EID: 9144234775     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Brophy JM, Deslauriers G, Boucher B, Rouleau JL. The hospital course and short term prognosis of patients presenting to the emergency room with decompensated congestive heart failure. Can J Cardiol 1993;9:219-24.
2. Johansen H, Strauss B, Arnold JMO, Moe G, Liu P. On the rise: The current and projected future burden of congestive heart failure hospitalization in Canada. Can J Cardiol 2003;19:430-5.
3. Howlett JG, Johnstone DE, Sketris I, O'Reilly M, Horne GS, Cox JL. Identifying opportunities to address the congestive heart failure burden: The Improving Cardiovascular Outcomes in Nova Scotia (ICONS) study. Can J Cardiol 2003;19:439-44.
4. Liu P, Arnold M, Belenkie I, et al. The 2001 Canadian Cardiovascular Society consensus guideline update for the management and prevention of heart failure. Can J Cardiol 2001;17(Suppl E):1E-24E.
5. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). American College of Cardiology Web site. (Version current at July 14, 2004).
6. Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - pharmacological approaches. J Card Fail 1999;5:357-82 (erratum in J Card Fail 2000;6:74).
7. MERIT-HF study group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
8. Packer M, Bristow MR, Cohn JN, et al, for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
9. Packer M, Fowler MB, Roecker EB, et al, for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-9.
10. Pitt B, Zannad F, Remme WJ, et al, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
11. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100:2312-8.
12. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol 2003;41:56-61.
13. Luzier AB, DiTusa L. Underutilization of ACE inhibitors in heart failure. Pharmacotherapy 1999;19:1296-307.
14. Cleland JG, Cohen-Solal A, Aguilar JC, et al, for the IMPROVEMENT of Heart Failure Programme Committees and Investigators; Improvement programme in evaluation and management; Study Group on Diagnosis of the Working Group on Heart Failure of The European Society of Cardiology. Management of heart failure in primary care (the IMPROVEMENT of heart failure programme): An international survey. Lancet 2002;360:1631-9.
15. McAlister FA, Teo KK, Taher M, et al. Insights into the contemporary epidemiology and outpatient management of congestive heart failure. Am Heart J 1999;138:87-94.
16. Gattis WA, Larsen RL, Hasselblad V, Bart BA, O'Connor CM. Is optimal angiotensin-converting enzyme inhibitor dosing neglected in elderly patients with heart failure? Am Heart J 1998;136:43-8.
17. Chen YT, Wang Y, Radford MJ, Krumholz HM. Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure. Am Heart J 2001;141:410-7.
18. Kermani M, Dua A, Gradman AH. Underutilization and clinical benefits of angiotensin-converting enzyme inhibitors in patients with asymptomatic left ventricular dysfunction. Am J Cardiol 2000;86:644-8.
19. Weil E, Tu JV. Quality of congestive heart failure treatment at a Canadian teaching hospital. CMAJ 2001;165:284-7.
20. Bart BA, Gattis WA, Diem SJ, O'Connor CM. Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. Am J Cardiol 1997;79:1118-20.
21. Frances CD, Noguchi H, Massie BM, Browner WS, McClellan M. Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. Arch Intern Med 2000;160:2645-50.
22. Gattis WA, Hasselblad V, Whelan DJ, O'Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: Results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch Intern Med 1999;159:1939-45.
23. Luzier AB, Forrest A, Feuerstein SG, Schentag JJ, Izzo JL Jr. Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization. Am J Cardiol 2000;86:519-23.
24. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1190-5.
25. Cline CM, Israelsson BY, Willenheimer RB, Broms K, Erhardt LR. Cost effective management programme for heart failure reduces hospitalization. Heart 1998;80:442-6.
26. Fonarow GC, Stevenson LW, Walden JA, et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol 1997;30:725-32.
27. Hanumanthu S, Butler J, Chomsky D, Davis S, Wilson JR. Effect of a heart failure program on hospitalization frequency and exercise tolerance. Circulation 1997;96:2842-8.
28. Tsuyuki RT, McKelvie RS, Arnold JM, et al. Acute precipitants of congestive heart failure exacerbations. Arch Intern Med 2001;161:2337-42.
29. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients. Arch Intern Med 2000;160:777-84.
30. Whellan DJ, Gaulden L, Gattis WA, et al. The benefit of implementing a heart failure disease management program. Arch Intern Med 2001;161:2223-8.
31. Krumholz HM, Amatruda J, Smith GL, et al. Randomized trial of an education and support intervention to prevent readmission of patients with heart failure. J Am Coll Cardiol 2002;39:83-9.
32. Kasper EK, Gerstenblith G, Hefter G, et al. A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission. J Am Coll Cardiol 2002;39:471-80.
33. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999;353:9-13.
34. Ramahi TM, Longo MD, Rohlfs K, Sheynberg N. Effect of heart failure program on cardiovascular drug utilization and dosage in patients with chronic heart failure. Clin Cardiol 2000;23:909-14.
35. Howlett JG, Johnstone DE, Cox JL. Seasonal variation in admission to hospital for congestive heart failure: Data from the ICONS study. Can J Cardiol 2002;18(Suppl B):124B-5B. (Abst)
36. Jong P, Liu PP, Thillaiampalam S, Johansen H. Seasonal variation in heart failure hospitalization and mortality in Canada. Can J Cardiol 2002;18(Suppl B):125B. (Abst)
37. Jong P, Thillaiampalam S, Johansen H, Liu PP. Triggers of seasonal variation in heart failure hospitalization and mortality. Can J Cardiol 2002;18(Suppl B):125B. (Abst)
38. Konstam MA, Dracup K, Baker DW, et al. Heart failure: Evaluation and care of patients with left ventricular systolic dysfunction. J Card Fail 1995;1:183-7.
39. American Society of Health-System Pharmacists. ASHP therapeutic guidelines on angiotensin-converting-enzyme inhibitors in patients with left ventricular dysfunction. Am J Health Syst Pharm 1997;54:299-313.